MedTrace Logo

ASV for Sleep Apnea After Myocardial Infarction

NCT02093377 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2021-09-21

No results posted yet for this study

Summary

The aim of this randomized controlled trial is to test the effect of 12 weeks Adaptive Servo-Ventilation (ASV) therapy (additionally to optimal medical management of myocardial infarction) on myocardial salvage (MSI=myocardial salvage/area at risk, primary endpoint).

Conditions

Interventions

DEVICE

Adaptive servo-ventilation

Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)

Sponsors & Collaborators

  • ResMed Foundation

    collaborator OTHER

  • University Hospital Regensburg

    lead OTHER

Principal Investigators

  • Michael Arzt, MD · University Hospital Regensburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02093377 on ClinicalTrials.gov